Creating Next Generation ADCs with Industry-Leading DAR Precision, Plasma Stability, & Tumor-Selective Linker Payload Activation

Time: 1:00 pm
day: day 1 track 2 am


• LCB’s novel next-generation
site-specific ADC platform
• Proprietary cancer-selective
linker providing significantly
improved therapeutic index
• Tumor-specific and ultra-potent
DNA-damaging crosslinking
payload with superior efficacy
and reduced toxicity